{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:12:35Z","timestamp":1786947155911,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100032668","name":"Kyowa Kirin International","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032668","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-025-01433-2","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T14:56:24Z","timestamp":1758207384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Effectiveness of Burosumab in Adults with X-Linked Hypophosphataemia (XLH) in the UK"],"prefix":"10.1007","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7576-250X","authenticated-orcid":false,"given":"Judith","family":"Bubbear","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin P. R.","family":"Clunie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Schini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syazrah","family":"Salam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Finezilber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Mathieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Davda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Barham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"1","key":"1433_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, de Lucas Collantes C, Schnabel D, Jandhyala R, Makitie O (2019) FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis 14(1):58. https:\/\/doi.org\/10.1186\/s13023-019-1014-8","journal-title":"Orphanet J Rare Dis"},{"key":"1433_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221117471","volume":"13","author":"ML Brandi","year":"2022","unstructured":"Brandi ML, Ariceta G, Beck-Nielsen SS, Boot AM, Briot K, de Lucas Collantes C, Emma F, Giannini S, Haffner D, Keen R, Levtchenko E, M\u04d3kitie O, Nilsson O, Schnabel D, Tripto-Shkolnik L, Zillikens MC, Liu J, Tudor A, Mughal MZ (2022) Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description. Ther Adv Chronic Dis 13:20406223221117471. https:\/\/doi.org\/10.1177\/20406223221117471","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"1433_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/sca.21141","volume":"36","author":"I Cremonesi","year":"2014","unstructured":"Cremonesi I, Nucci C, D\u2019Alessandro G, Alkhamis N, Marchionni S, Piana G (2014) X-linked hypophosphatemic rickets: enamel abnormalities and oral clinical findings. Scanning 36(4):456\u2013461. https:\/\/doi.org\/10.1002\/sca.21141","journal-title":"Scanning"},{"issue":"3","key":"1433_CR4","doi-asserted-by":"publisher","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739","volume":"107","author":"MK Javaid","year":"2022","unstructured":"Javaid MK, Ward L, Pinedo-Villanueva R, Rylands AJ, Williams A, Insogna K, Imel EA (2022) Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data. J Clin Endocrinol Metab 107(3):e1249\u2013e1262. https:\/\/doi.org\/10.1210\/clinem\/dgab739","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1433_CR5","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, Theodore-Oklota C, San Martin J (2019) The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc 3(7):1321\u20131334. https:\/\/doi.org\/10.1210\/js.2018-00365","journal-title":"J Endocr Soc"},{"issue":"3","key":"1433_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/rmdopen-2021-001714","volume":"7","author":"K Briot","year":"2021","unstructured":"Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N, Jan de Beur S, Javaid MK, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Nixon A, Nixon M, Sun W, Williams A, Imel EA (2021) Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open 7(3):5. https:\/\/doi.org\/10.1136\/rmdopen-2021-001714","journal-title":"RMD Open"},{"issue":"8","key":"1433_CR7","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab070","volume":"5","author":"M Cheung","year":"2021","unstructured":"Cheung M, Rylands AJ, Williams A, Bailey K, Bubbear J (2021) Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course. J Endocr Soc 5(8):bvab070. https:\/\/doi.org\/10.1210\/jendso\/bvab070","journal-title":"J Endocr Soc"},{"key":"1433_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02465-x","author":"SH Lo","year":"2020","unstructured":"Lo SH, Lachmann R, Williams A, Piglowska N, Lloyd AJ (2020) Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study. Qual Life Res. https:\/\/doi.org\/10.1007\/s11136-020-02465-x","journal-title":"Qual Life Res"},{"issue":"9","key":"1433_CR9","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1093\/rheumatology\/keaa859","volume":"60","author":"S Hawley","year":"2021","unstructured":"Hawley S, Shaw NJ, Delmestri A, Prieto-Alhambra D, Cooper C, Pinedo-Villanueva R, Javaid MK (2021) Higher prevalence of non-skeletal comorbidity related to X-linked hypophosphataemia: a UK parallel cohort study using CPRD. Rheumatology (Oxford) 60(9):4055\u20134062. https:\/\/doi.org\/10.1093\/rheumatology\/keaa859","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1433_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae102","volume":"8","author":"A Khan","year":"2024","unstructured":"Khan A, Johnson B, Nixon A, Dent JE, Li Z, Yang E, Williams A (2024) Association between work productivity and characteristics of adults with X-linked hypophosphatemia: an analysis of the XLH disease monitoring program. JBMR Plus 8(11):ziae102. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae102","journal-title":"JBMR Plus"},{"issue":"1","key":"1433_CR11","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, Kamenicky P, Nevoux J, Prie D, Rothenbuhler A, Wicart P, Harvengt P (2014) Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 3(1):R13-30. https:\/\/doi.org\/10.1530\/EC-13-0103","journal-title":"Endocr Connect"},{"issue":"2","key":"1433_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40272-020-00381-8","volume":"22","author":"V Saraff","year":"2020","unstructured":"Saraff V, Nadar R, Hogler W (2020) New developments in the treatment of X-linked hypophosphataemia: implications for clinical management. Paediatr Drugs 22(2):113\u2013121. https:\/\/doi.org\/10.1007\/s40272-020-00381-8","journal-title":"Paediatr Drugs"},{"issue":"10189","key":"1433_CR13","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Hogler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393(10189):2416\u20132427. https:\/\/doi.org\/10.1016\/S0140-6736(19)30654-3","journal-title":"Lancet"},{"issue":"3","key":"1433_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","volume":"107","author":"A Linglart","year":"2022","unstructured":"Linglart A, Imel EA, Whyte MP, Portale AA, Hogler W, Boot AM, Padidela R, Van\u2019t Hoff W, Gottesman GS, Chen A, Skrinar A, Scott Roberts M, Carpenter TO (2022) Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107(3):813\u2013824. https:\/\/doi.org\/10.1210\/clinem\/dgab729","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1433_CR15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenicky P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO, Investigators A (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33(8):1383\u20131393. https:\/\/doi.org\/10.1002\/jbmr.3475","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1433_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K (2019) Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int 105(3):271\u2013284. https:\/\/doi.org\/10.1007\/s00223-019-00568-3","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"1433_CR17","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna KL, Rauch F, Kamenicky P, Ito N, Kubota T, Nakamura A, Zhang L, Mealiffe M, San Martin J, Portale AA (2019) Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res 34(12):2183\u20132191. https:\/\/doi.org\/10.1002\/jbmr.3843","journal-title":"J Bone Miner Res"},{"key":"1433_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002676","author":"P Kamenicky","year":"2023","unstructured":"Kamenicky P, Briot K, Brandi ML, Cohen-Solal M, Crowley RK, Keen R, Kolta S, Lachmann RH, Lecoq AL, Ralston SH, Walsh JS, Rylands AJ, Williams A, Sun W, Nixon A, Nixon M, Javaid MK (2023) Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2022-002676","journal-title":"RMD Open"},{"key":"1433_CR19","unstructured":"FDA. Crysvita Prescribing Information. 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761068s000lbl.pdf"},{"key":"1433_CR20","unstructured":"Health Canada. Health Canada. Regulatory Decision Summary - Crysvita. . 2018.Available from: https:\/\/hpr-rps.hres.ca\/reg-content\/regulatory-decision-summary-detail.php?linkID=RDS00463"},{"key":"1433_CR21","unstructured":"MHLW. Report on the Deliberation Results, Crysvita Subcutaneous Injection 10 mg, 20 mg, 30 mg. 2019. Available from: https:\/\/www.pmda.go.jp\/files\/000235589.pdf"},{"key":"1433_CR22","unstructured":"EMA. Crysvita Summary of Product Characteristics. European Medicines Agency; 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/crysvita-epar-product-information_en.pdf"},{"key":"1433_CR23","unstructured":"NICE. Burosumab for treating X-linked hypophosphataemia in adults. Technology Appraisal Guidance TA993. 2024. Available from: https:\/\/www.nice.org.uk\/guidance\/TA993"},{"key":"1433_CR24","unstructured":"NHS England. Early Access to Medicines Scheme. 2025. Available from: https:\/\/www.england.nhs.uk\/aac\/what-we-do\/how-can-the-aac-help-me\/eams\/"},{"key":"1433_CR25","unstructured":"Stein D, Soni, M,. (2018) Early Access Programs - Opportunities and Challenges for Real-World Data Collection. The Evidence Forum Spring"},{"key":"1433_CR26","unstructured":"Bellamy N. WOMAC osteoarthritis index user guide. Version XI Brisbane, Australia; 2012."},{"key":"1433_CR27","unstructured":"Cleeland CS. The Brief Pain Inventory. User Guide. 2009."},{"key":"1433_CR28","unstructured":"EuroQol. EQ-5D-5L. 2024.Available from: https:\/\/euroqol.org\/information-and-support\/euroqol-instruments\/eq-5d-5l\/"},{"issue":"1","key":"1433_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","volume":"27","author":"NJ Devlin","year":"2018","unstructured":"Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B (2018) Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ 27(1):7\u201322. https:\/\/doi.org\/10.1002\/hec.3564","journal-title":"Health Econ"},{"issue":"suppl 3","key":"1433_CR30","first-page":"S870","volume":"22","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Theodore-Oklota C, Bonner N, Arbuckle R, Williams A, Nixon A (2019) Confirmatory psychometric validation of the Western Ontario and McMaster Universities Osteoarthritis Inventory (WOMAC) in adult X-linked hypophosphatemia (XLH). Value Health 22(suppl 3):S870","journal-title":"Value Health"},{"key":"1433_CR31","doi-asserted-by":"crossref","unstructured":"Skrinar A, Theodore-Oklota C, Bonner N, Arbuckle R, Williams A, Nixon A. Confirmatory psychometric validation of the Brief Pain Inventory (BPI-SF) in adult X-linked hypophosphatemia (XLH). ISPOR; 2019; Copenhagen, Denmark.","DOI":"10.1016\/j.jval.2019.09.2483"},{"key":"1433_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1289365","author":"R Claire","year":"2024","unstructured":"Claire R, Elvidge J, Hanif S, Goovaerts H, Rijnbeek P, Jonsson P, Facey K, Dawoud D (2024) International collaboration - advancing the use of real-world evidence in health technology assessment. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1289365","journal-title":"Front Pharmacol"},{"key":"1433_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/jpps.2023.11460","volume":"26","author":"P Graili","year":"2023","unstructured":"Graili P, Guertin JR, Chan KKW, Tadrous M (2023) Integration of real-world evidence from different data sources in health technology assessment. J Pharm Pharm Sci 26:11460. https:\/\/doi.org\/10.3389\/jpps.2023.11460","journal-title":"J Pharm Pharm Sci"},{"issue":"8","key":"1433_CR34","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s40618-025-02596-3","volume":"48","author":"GP Arcidiacono","year":"2025","unstructured":"Arcidiacono GP, Camozzi V, Tripepi G, Eller-Vainicher C, Vezzoli G, Brandi ML, Marcucci G, Girasole G, Aversa A, Vitale C, Cerbone G, D\u2019Alessandro MM, Zaninotto M, Fusaro M, Torres MO, Cannito M, Cecchinato A, Diogo M, Peleg Falb M, Guidolin F, Zampogna M, Plebani M, Campello E, Simioni P, Sella S, Giannini S (2025) Predictors of response to burosumab in adults with X-linked hypophosphatemia: real-world data from an Italian cohort. J Endocrinol Invest 48(8):1857\u20131869. https:\/\/doi.org\/10.1007\/s40618-025-02596-3","journal-title":"J Endocrinol Invest"},{"key":"1433_CR35","unstructured":"NICE. NICE health technology evaluations: the manual - Introduction to health technology evaluation. 2023. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation"},{"key":"1433_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002286","author":"AJK Ostor","year":"2022","unstructured":"Ostor AJK, Soliman AM, Papp KA, Padilla B, Wang Z, Eldred A, de Vlam K, Kivitz A (2022) Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the phase 3 trial keepsake 2. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2022-002286","journal-title":"RMD Open"},{"issue":"1","key":"1433_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-022-05029-x","volume":"23","author":"PG Conaghan","year":"2022","unstructured":"Conaghan PG, Abraham L, Viktrup L, Cislo P (2022) Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis. BMC Musculoskelet Disord 23(1):106. https:\/\/doi.org\/10.1186\/s12891-022-05029-x","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"1433_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13075-022-02813-x","volume":"24","author":"M Bergman","year":"2022","unstructured":"Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, Song Y, Wright GC (2022) Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. Arthritis Res Ther 24(1):155. https:\/\/doi.org\/10.1186\/s13075-022-02813-x","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1433_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13023-023-02620-w","volume":"18","author":"S Cole","year":"2023","unstructured":"Cole S, Sanchez-Santos MT, Kolovos S, Javaid MK, Pinedo-Villanueva R (2023) Patient-reported outcomes measures of X-linked hypophosphataemia participants: findings from a prospective cohort study in the UK. Orphanet J Rare Dis 18(1):26. https:\/\/doi.org\/10.1186\/s13023-023-02620-w","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1433_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0538-4","volume":"11","author":"L Forestier-Zhang","year":"2016","unstructured":"Forestier-Zhang L, Watts L, Turner A, Teare H, Kaye J, Barrett J, Cooper C, Eastell R, Wordsworth P, Javaid MK, Pinedo-Villanueva R (2016) Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia. Orphanet J Rare Dis 11(1):160. https:\/\/doi.org\/10.1186\/s13023-016-0538-4","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1433_CR41","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s13023-022-02452-0","volume":"17","author":"MIL Yanes","year":"2022","unstructured":"Yanes MIL, Diaz-Curiel M, Peris P, Vicente C, Marin S, Ramon-Krauel M, Hernandez J, Broseta JJ, Espinosa L, Mendizabal S, Perez-Sukia L, Martinez V, Palazon C, Pinero JA, Calleja MA, Espin J, Arborio-Pinel R, Ariceta G (2022) Health-related quality of life of X-linked hypophosphatemia in Spain. Orphanet J Rare Dis 17(1):298. https:\/\/doi.org\/10.1186\/s13023-022-02452-0","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1433_CR42","doi-asserted-by":"publisher","first-page":"e1061","DOI":"10.1210\/clinem\/dgad642","volume":"109","author":"KL Insogna","year":"2024","unstructured":"Insogna KL, Sullivan R, Parziale S, Deng Y, Carrano D, Simpson C, Dufour S, Carpenter T, Petersen KF (2024) Effect of burosumab on muscle function and strength, and rates of ATP synthesis in skeletal muscle in adults with XLH. J Clin Endocrinol Metab 109(3):e1061\u2013e1071. https:\/\/doi.org\/10.1210\/clinem\/dgad642","journal-title":"J Clin Endocrinol Metab"},{"key":"1433_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2024.101819","volume":"24","author":"C Jarvis","year":"2025","unstructured":"Jarvis C, Ramakrishnan R, Dharmaraj P, Mushtaq T, Gupta S, Williams A, Rylands AJ, Barham H, Nixon A, Uday S (2025) Impact of stopping burosumab treatment at the end of skeletal growth in adolescents with X-linked hypophosphatemia (XLH). Bone Rep 24:101819. https:\/\/doi.org\/10.1016\/j.bonr.2024.101819","journal-title":"Bone Rep"},{"key":"1433_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2024.104958","volume":"70","author":"GI Baroncelli","year":"2024","unstructured":"Baroncelli GI, Grandone A, Aversa A, Sessa MR, Pelosini C, Michelucci A, Toschi B, Manca M, Isola A, Comberiati P (2024) Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets. Eur J Med Genet 70:104958. https:\/\/doi.org\/10.1016\/j.ejmg.2024.104958","journal-title":"Eur J Med Genet"},{"issue":"1","key":"1433_CR45","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s13023-023-02882-4","volume":"18","author":"G Ariceta","year":"2023","unstructured":"Ariceta G, Beck-Nielsen SS, Boot AM, Brandi ML, Briot K, de Lucas Collantes C, Emma F, Giannini S, Haffner D, Keen R, Levtchenko E, M\u04d3kitie O, Mughal MZ, Nilsson O, Schnabel D, Tripto-Shkolnik L, Liu J, Williams A, Wood S, Zillikens MC (2023) The international X-linked hypophosphatemia (XLH) registry: first interim analysis of baseline demographic, genetic and clinical data. Orphanet J Rare Dis 18(1):304. https:\/\/doi.org\/10.1186\/s13023-023-02882-4","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1433_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01434-4","volume":"15","author":"R Padidela","year":"2020","unstructured":"Padidela R, Nilsson O, Makitie O, Beck-Nielsen S, Ariceta G, Schnabel D, Brandi ML, Boot A, Levtchenko E, Smyth M, Jandhyala R, Mughal Z (2020) The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study. Orphanet J Rare Dis 15(1):172. https:\/\/doi.org\/10.1186\/s13023-020-01434-4","journal-title":"Orphanet J Rare Dis"},{"key":"1433_CR47","unstructured":"NHS. Blood Sciences Reference Range Database (BSHC-REC-317b version 3.13). 2024.Available from: Blood-Sciences-Reference-Range-Database_BSHC-REC-317-v3.pdf"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01433-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-025-01433-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01433-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T13:21:54Z","timestamp":1766755314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-025-01433-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1433"],"URL":"https:\/\/doi.org\/10.1007\/s00223-025-01433-2","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JB received support from Kyowa Kirin for the data collection and analysis and medical writing for the current study and paper, and has received advisory board consultancy fees and honouraria from Kyowa Kirin. EM has been a clinical investigator on other burosumab studies. MS has received honouraria\/speaking fees and funding for conference attendance from UCB. GPRC has received medical writing, consultation fees, honouraria, support for conference attendance and funding for a research nurse from Kyowa Kirin, and honouraria from Pharmacosmos. MR has received funding to attend conference from Eli Lilly. RK has received payments from KKI for data collection and analysis, medical writing, consultancy, speaker honouraria and travel support for conference attendance. DS contracted to Bionical Emas Ltd and received payment for services relating data collection and resulting publications in the current study. RD is a full-time employee of Bionical Emas Ltd, which received payment for services relating to data collection and resulting publications in the current study. BJ, GL and VH are employees of Kyowa Kirin. AB, HB and MN were employed by, or contracted to, Chilli Consulting Ltd at the time of the study and received payment from Kyowa Kirin for data analysis and medical writing. RL, GK, JW, LM, SS, YL and RK have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol and supporting documents were approved by the East Midlands \u2013 Leicester South Research Ethics Committee (ref 23\/EM\/0078) and the NHS Health Research Authority and Health Research Wales (IRAS project ID 321609; 9 May 2023).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Informed consent was not collected from patients as no identifiable data were accessed outside the direct care team.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}],"article-number":"122"}}